Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics

INTRODUCTION: In the INBUILD trial in patients with progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (IPF), nintedanib slowed the rate of decline in forced vital capacity (FVC; mL/year) over 52 weeks compared with placebo. We assessed the efficacy of nintedanib across subgroup...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolb, Martin, Flaherty, Kevin R., Silva, Rafael S., Prasse, Antje, Vancheri, Carlo, Mueller, Heiko, Sroka-Saidi, Kamila, Wells, Athol U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611817/
https://www.ncbi.nlm.nih.gov/pubmed/37751022
http://dx.doi.org/10.1007/s12325-023-02668-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611817/
https://www.ncbi.nlm.nih.gov/pubmed/37751022
http://dx.doi.org/10.1007/s12325-023-02668-x

Ejemplares similares